BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

Public investors again showed their appetite for protein degradation companies Friday, as C4’s upsized IPO was the largest and best-received of three new NASDAQ listings.  Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), a preclinical company based...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

Led by Bing Li and Debra Yu, Perceptive’s LianBio has launched with the goal of speeding the entrance of new medicines into Asian markets, leading with a registration-ready cardiomyopathy candidate from MyoKardia and a Phase...
BioCentury | May 18, 2020
Product Development

Preclinical data suggest Oxford vaccine could reduce COVID-19 symptoms, won’t provide herd immunity

Preclinical data from a leading COVID-19 vaccine candidate from Oxford University suggest that it may be more like the flu vaccine than the smallpox jab, reducing the severity of symptoms but not preventing infection. Such...
BioCentury | Jan 30, 2020
Distillery Therapeutics

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); breast cancer; small cell lung cancer A University of Florida team led by Dialectic Therapeutics Inc. co-founders Guangrong Zheng and Daohong Zhou showed the company’s lead candidate,...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Sep 7, 2018
Financial News

Qiming, Hillhouse lead Jacobio's $55M series C

Cancer company Beijing Jacobio Pharmaceutical Co. Ltd. (Beijing, China) raised $55 million in a series C round led by Qiming Venture Capital and Hillhouse Capital. Prudence Investment Management also participated. Jacobio's lead candidate JAB-3068, a...
BioCentury | Sep 6, 2018
Finance

Jacobio’s ladder

Beijing Jacobio Pharmaceutical Co. Ltd. plans to use its $55 million series C round to fuel its creation of spinouts housing internally developed assets. Existing investor Qiming Venture Partners led the tranched round, which closed...
BioCentury | Aug 31, 2018
Financial News

Qiming, Hillhouse lead Jacobio's $55M series C

Cancer company Beijing Jacobio Pharmaceutical Co. Ltd. (Beijing, China) raised $55 million in a series C round led by Qiming Venture Capital and Hillhouse Capital. Prudence Investment Management also participated. Jacobio's lead candidate JAB-3068, a...
BioCentury | Aug 2, 2018
Politics & Policy

Bach says supply chain cops one-third of drug spending

An analysis by Peter Bach and colleagues at Memorial Sloan Kettering Cancer Center found that nearly one-third of the $480 billion spent in the U.S. on pharmaceuticals in 2016 was captured as gross profits in...
BioCentury | Jan 17, 2018
Distillery Therapeutics

Inflammation

INDICATION: Allergy Cell culture studies suggest a CD23-mimicking single-domain antibody against IgE could help treat allergy. The single-domain neutralizing antibody mimics CD23, the low-affinity Fc receptor for IgE, to bind IgE with a K d...
Items per page:
1 - 10 of 49